Signet Healthcare Partners
VC Fund
New York, United States
Signet Healthcare Partners is a VC fund in New York focused on Biotechnology and Health Care. Based in New York, U.S., Signet Healthcare Partners aims to invest in commercial-stage companies in the healthcare industry.
- Total investments:
- 25
- Last investment:
- Lead investor:
- 64%
- Fund size:
- $137M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Signet Healthcare Partners invests in
Stages Signet Healthcare Partners invests in
Countries Signet Healthcare Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Ashley Friedman
|
|||
James C. Gale
|
|||
Jerald S. Cobbs
|
|||
Joyce Erony
|
|||
1 more contact available
Investment Focus
Industry
- Biotechnology 15 (60%)
- Health Care 12 (48%)
- Pharmaceutical 12 (48%)
- Manufacturing 7 (28%)
- Medical Device 5 (20%)
Stage
- Series B 5 (20%)
- Funding Round 5 (20%)
- Private Equity 4 (16%)
- Series A 3 (12%)
- Series C 3 (12%)
Country
- United States 15 (60%)
- Germany 2 (8%)
- Israel 1 (4%)
- Norway 1 (4%)
- Sweden 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ashley Friedman
Managing Director
|
Managing Director | Total investments: 4 | Find email | |
|
James C. Gale
Managing Director/Founding Partner
|
Managing Director/Founding Partner | Total investments: 9 | Find email | |
|
Jerald S. Cobbs
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Joyce Erony
Managing Director
|
Managing Director | Total investments: 9 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
PainTEQ
|
PainTEQ provides solutions and services to the interventional pain management community. | Venture - Series Unknown / Aug 27, 2025 | |
NorthX Biologics
|
NorthX Biologics offer services and support in the development and manufacturing of biologics. | Private Equity / May 14, 2025 | |
leon nanodrugs
|
leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs.leon-nanodrugs offers access to the next generation of nano-formulated drugswith meaningful differentiation and added patient benefits.They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles. | Series D / Aug 06, 2024 | |
Curida
|
Curida is a pharmaceutical contract development and manufacturing organization (CDMO) with core competence on Blow-Fill-Seal, Spray and Bottles. | Private Equity / Apr 15, 2024 | |
Paragonix Technologies
|
Paragonix Technologies is a medical device company developing first-in class Organ Preservation and Transport Systems for optimum quality transplant organs. They recognize that simplicity and ease-of-use of organ preservation technologies are paramount to the change needed in transplantation medicine. | $24M / Series B / Mar 07, 2023 | |
Juno Pharmaceuticals
|
Juno Pharmaceuticals produces and distributes amoxicillin, hydrochloride syringes, hydromorphone solutions, phentermine tablets & capsules. | Private Equity / Feb 24, 2022 | |
Ascendia Pharmaceutical Solutions
|
Ascendia Pharmaceutical Solutions is a US-based specialty CDMO that offers a comprehensive suite of DP formulation development and manufacturing services for preclinical- and clinical-stage drug candidates. It specializes in improving the solubility, bioavailability and/or stability of both small molecule and biologic drugs using its suite ofnanotechnology platforms. Ascendia formulates products for injectable, oral, topical and transmucosal/ophthalmic routes of administration. The company has four technology platforms - EmulSol(r) for producing nano/micro-emulsions, AmorSol(r) for creating amorphous solid dispersions, NanoSol(r) for formulating nanoparticles, and LipidSol(r) for liposome and LNP formulations. Ascendia has a cGMP facility that scale-up formulations for tox/IND-enabling studies and also supply clinical trial materials in its aseptic and non-aseptic manufacturing suites. | Venture - Series Unknown / Apr 08, 2021 | |
Smart Medical Systems
|
SMART Medical Systems Ltd, provides enabling medical devices that revolutionize the concept and practice of gastrointestinal (GI) endoscopy. The company focuses on innovative devices with the vision of providing widespread, cost-effective solutions, enabling superior endoscopy for the benefit of both doctors and patients.SMART is lead by ahighly dedicated team of professionals and has established close relations with outsource manufacturing facilitiies for the production of its products. SMART is backed by high level private investors.SMART’s proprietary balloon technology is implemented in its various products.SMART’s flagship product – the G-EYE™ endoscope is a unique and innovative device enabling the increasing of polyp detection rate in the day to day colonoscopy in a simple and intuitive manner. By implementing its balloon technology into the G-EYE™ system, the endoscope enables Controlled Withdrawal™ of the endoscope during colonoscopy, thus improving visibility of the colon and making therapy and intervention much easier and faster. The G-EYE™ together with SMART’s single balloon disposables can also act as an optimized two-balloon system for deep small bowel enteroscopy and double balloon colonoscopy.SMART is ISO 13485:2003 certified by the European regulatory authorities, and maintains a comprehensive quality assurance approach to ensure the quality of its products | $8M / Series B / Feb 14, 2018 | |
Leading Pharma
|
Leading Pharma is a privately owned generic pharmaceutical company that purchases, licenses, develops, manufactures and distributes high-quality, safe and effective products to drugstore chains, distributors, wholesalers, mass merchandisers, government agencies and managed care accounts in the U.S. Their products are available in various dosageforms across many therapeutic areas under the Leading label.At Leading, their mission is simple: to provide quality, affordable, safe and effective pharmaceutical products to the people who need them. Their team is dedicated to providing their customers with outstanding customer service, innovative marketing strategies, quality manufacturing, efficient distribution and stringent regulatory compliance to ensure safety every step of the way. | $40M / Jan 08, 2018 | |
TELA Bio
|
TELA Bio is a life science company that specializes in soft tissue reconstruction. The company aims to commercialize a portfolio of products that are purposefully designed to address a range of unmet needs in soft tissue repair. | $25M / Oct 30, 2017 | |
| See all 25 investments → | |||
Co-Investors
Pharmascience
3 deals together
TVM Capital Life Science
3 deals together
Athyrium Capital Management LP
2 deals together
Hildred Capital Partners
2 deals together
TVM Capital
2 deals together
Albany Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Signet Healthcare Partners invest in?
Signet Healthcare Partners invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Funding Round stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Signet Healthcare Partners?
Public channels for Signet Healthcare Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Signet Healthcare Partners?
The team at Signet Healthcare Partners includes Ashley Friedman (Managing Director), James C. Gale (Managing Director/Founding Partner) and Jerald S. Cobbs (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
